Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model

Ruzafa, Javier Cid; Merinopoulou, Evie; Baggaley, Rebecca F.; Leighton, Pamela; Werther, Winifred; Felici, Diana; Cox, Andrew

doi:10.1002/pds.3927

Cited by 36 publications

(21 citation statements)

References 60 publications

(93 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,18,19 The estimated world-wide 5-year prevalence is approximately 230,000 patients. 20 In the Western world, the age-standardized incidence has been reported to be approximately 5 cases per 100,000. 21,22 The median age of patients at diagnosis is approximately 66–70 years with 37% of patients being younger than 65 years of age.…”

Section: Multiple Myeloma Epidemiology: Incidence Survival and Racimentioning

confidence: 99%

Multiple myeloma epidemiology and survival: A unique malignancy

Kazandjian

2016

Seminars in Oncology

568

418

View full text Add to dashboard Cite

Multiple myeloma (MM), although a rare disease, is the second most common hematologic malignancy. It is found in the spectrum of plasma cell dyscrasias which begins with monoclonal gammopathy of unknown significance to overt plasma cell leukemia and extramedullary myeloma. MM is associated with significant morbidity due to its end-organ destruction. It is a disease of the older population and its incidence in the African American population is twice that of the European American population. Improvements in the treatment of MM in the past couple of decades, beginning with the use of autologous stem cell transplantation followed by availability of novel treatments such as immunomodulatory drugs and proteasome inhibitors has transformed the natural history of the disease leading to longer survival times. Advancements in the diagnosis, monitoring, and treatment of MM are of the utmost importance as the general population lives longer due to other improvements in health care. The recent introduction of novel therapies has been paralleled by advancements in the monitoring of MM, namely, by the availability exquisitely sensitive techniques in detecting minimal residual disease. As drug development and technology continues to improve, it will be important to design rationale clinical trials enrolling patient populations which represent the overall population including racial minorities and the elderly so trial results can be appropriately extrapolated. This manuscript reviews the changing epidemiology, the improvements in survival, and the health disparity observed in important subgroups of MM.

show abstract

Section: Multiple Myeloma Epidemiology: Incidence Survival and Racimentioning

confidence: 99%

Multiple myeloma epidemiology and survival: A unique malignancy

Kazandjian

2016

Seminars in Oncology

568

418

View full text Add to dashboard Cite

show abstract

“…Treatment of elderly MM patients at relapse is often challenging, in part due to the fact that the number of therapeutic lines that can be endured is limited compared to younger and fitter patients. 59 Advanced age, coexisting comorbidities, toxicities from previous therapies and an aggressive pattern of relapse may also reduce the spectrum of feasible salvage therapies. 6 The analysis of the risk/benefit ratio of each agent is therefore pivotal to individualize treatment.…”

Section: Treatment Of Relapsed/refractory Elderly MM Patientsmentioning

confidence: 99%

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

et al. 2018

View full text Add to dashboard Cite

Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy of the general population, its incidence is expected to grow in the future. Elderly patients represent a particular challenge due to their marked heterogeneity. Many new and highly effective drugs have been introduced in the last few years and results from clinical trials are promising. Besides the availability of novel agents, a careful evaluation of elderly patients showed to be a key factor for the success of therapy. A geriatric assessment is a valid strategy to better stratify patients. In particular, different scores are available today to appropriately assess elderly patients and define their fitness/frailty status. The choice of treatment-transplantation, triplets, doublets, or reduced-dose therapies including novel agents-should depend on the patient's fitness status (fit, intermediate-fit or frail). Second-generation novel agents have also been evaluated as salvage therapy in the elderly, and these new agents certainly represent a further step forward in the treatment armamentarium for elderly patients with multiple myeloma.

show abstract

“…Географическионашироковарьируетвразныхрегионах мира и максимальна в индустриализованных районах Австралии, Новой Зеландии, Европы и Северной Америки [7]. Заболеваемость ММ в США всреднемсоставляет4-5новыхслучаев,средипопу-ляцииафроамериканцевможетдостигать9-10забо-левшихна100тыс.населениявгод [8,9].Напротив, встранахВосточнойАзии,вчастностивЯпонии,этот показательнижеинепревышает1,2случаяна100тыс. населениявгод [10].Кстранамснизкойзаболеваемостью ММ относятся Южная Корея (1,4) [11], Китай (1,3) [12]иТайвань (1,8случаяна100тыс.населения вгод) [13].…”

Section: о н к о г е м а т о л о г и я 3 ' 2 017 т о м 1 2 O N C O H unclassified

Epidemiology of Multiple Myeloma According to the Кirov Region Population Registers

Лучинин¹,

Семочкин²,

Минаева³

et al. 2017

Onkogematologiâ

View full text Add to dashboard Cite

Introduction. The epidemiology of multiple myeloma (MM) in Russia is poorly understood. Available data are limited. The aim of this study was to analyze the basic epidemiological parameters of MM in the Kirov region based on own regional population register data. Materials and methods. Five hundred and sixty-seven patients with newly diagnosed MM between 1994 and 2016 were included. The median age was 64 years (range, 29-90). The age-standardized incidence of MM in Kirov region was 1.8 cases per 100.000/year. results. During research period (23 years) we have the positive trend of the incidence and prevalence of MM and negative tendency of mortality every year. Our prognosis of the intensive incidence in Kirov region is 2.2-2.3 cases per 100.

show abstract

Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model

Cited by 36 publications

References 60 publications

Multiple myeloma epidemiology and survival: A unique malignancy

Multiple myeloma epidemiology and survival: A unique malignancy

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Epidemiology of Multiple Myeloma According to the Кirov Region Population Registers

Contact Info

Product

Resources

About